المؤلفون: Kaiser, M Dimopoulos, MA Gay, F Schjesvold, FH Beksac, M Hajek, R Weisel, KC Goldschmidt, H Maisnar, V Moreau, P others

مصطلحات موضوعية: Health Sciences, Επιστήμες Υγείας

URL الوصول: https://explore.openaire.eu/search/publication?articleId=dedup_wf_001::5e2826f83798d3258136d0215e6c0b2a
https://pergamos.lib.uoa.gr/uoa/dl/object/uoadl:2954851

المؤلفون: Gregersen, H, Peceliunas, V, Remes, K, Schjesvold, FH, Abildgaard, N, Nahi, H, Andersen, NF, Vangsted, AJ, Klausen, TW, Helleberg, C, Carlson, K, Frolund, UC, Axelsson, P, Stromberg, O, Blimark, CH, Linder, O, Tsykunova, G, Waage, A, Hansson, M, Gulbrandsen, N

المصدر: BLOOD. 134

مصطلحات موضوعية: Medicin och hälsovetenskap

URL الوصول: http://kipublications.ki.se/Default.aspx?queryparsed=id:143416253

المؤلفون: Guenther, A, Mugge, LO, Haenel, M, Schjesvold, FH, Lechner, D, Yaser, S, Hebart, H, Gisslinger, H, Greil, R, Gunsilius, E, Goerner, M, Weisel, K, Durig, J, Elemary, M, Wolleschak, D, Klein, SA, Munder, M, Kiani, A, Nahi, H, Junghanss, C, Campello-Iddison, V, Deniau, Y, Feng, XS, Einsele, H

المصدر: BLOOD. 128(22)

مصطلحات موضوعية: Medicin och hälsovetenskap

URL الوصول: http://kipublications.ki.se/Default.aspx?queryparsed=id:135236042

المؤلفون: Pawlyn C; The Institute of Cancer Research, London, UK. charlotte.pawlyn@icr.ac.uk.; The Royal Marsden Hospital NHS Foundation Trust, London, UK. charlotte.pawlyn@icr.ac.uk., Schjesvold FH; Oslo Myeloma Center, Department of Hematology, Oslo University Hospital, Oslo, Norway.; KG Jebsen Center for B Cell Malignancies, University of Oslo, Oslo, Norway., Cairns DA; Leeds Cancer Research UK Clinical Trials Unit of Leeds, Leeds, UK., Wei LJ; Department of Biostatistics, Harvard T.H. Chan School of Public Health, Boston, MA, USA., Davies F; Perlmutter Cancer Center, NYU Langone, New York, NY, USA., Nadeem O; Dana-Farber Cancer Institute, Boston, MA, USA., Abdulhaq H; University of California, San Francisco, Fresno Campus, CA, USA., Mateos MV; University Hospital of Salamanca; IBSAL; Institute of Cancer Molecular and Cellular Biology; and CIBERONC, Salamanca, Spain., Laubach J; Dana-Farber Cancer Institute, Boston, MA, USA., Weisel K; University Medical Center of Hamburg-Eppendorf, Hamburg, Germany., Ludwig H; Medical Department Center for Oncology, Hematology and Palliative Medicine, Wilhelminen Cancer Research Institute, Vienna, Austria., Rajkumar SV; Division of Hematology, Mayo Clinic, Rochester, MN, USA., Sonneveld P; Department of Hematology, Erasmus MC Cancer Institute, Rotterdam, The Netherlands., Jackson G; Northern Centre for Cancer Care, Newcastle Upon Tyne Hospitals Trust, Newcastle Upon Tyne, UK., Morgan G; Perlmutter Cancer Center, NYU Langone, New York, NY, USA., Richardson PG; Dana-Farber Cancer Institute, Boston, MA, USA.

المصدر: Blood cancer journal [Blood Cancer J] 2024 Aug 12; Vol. 14 (1), pp. 134. Date of Electronic Publication: 2024 Aug 12.

نوع المنشور: Journal Article; Review

بيانات الدورية: Publisher: Nature Pub. Group Country of Publication: United States NLM ID: 101568469 Publication Model: Electronic Cited Medium: Internet ISSN: 2044-5385 (Electronic) Linking ISSN: 20445385 NLM ISO Abbreviation: Blood Cancer J Subsets: MEDLINE

مواضيع طبية MeSH: Multiple Myeloma*/mortality , Multiple Myeloma*/therapy , Multiple Myeloma*/drug therapy , Progression-Free Survival*, Humans ; Clinical Trials as Topic ; Neoplasm, Residual ; Biomarkers

المؤلفون: Hamnvik LHD; Oslo Myeloma Center, Department of Hematology, Oslo University Hospital, Oslo, Norway. Electronic address: lahdah@ous-hf.no., Eide-Olsen S; Institute of Clinical Medicine, University of Oslo, Oslo, Norway., Fosseng A; Division of Cancer Medicine, Oslo University Hospital, Oslo, Norway., Schjesvold FH; Oslo Myeloma Center, Department of Hematology, Oslo University Hospital, Oslo, Norway.

المصدر: Clinical lymphoma, myeloma & leukemia [Clin Lymphoma Myeloma Leuk] 2024 Jul 31. Date of Electronic Publication: 2024 Jul 31.

نوع المنشور: Journal Article

بيانات الدورية: Publisher: Elsevier Country of Publication: United States NLM ID: 101525386 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 2152-2669 (Electronic) Linking ISSN: 21522669 NLM ISO Abbreviation: Clin Lymphoma Myeloma Leuk Subsets: MEDLINE

المؤلفون: Schjesvold FH; Oslo Myeloma Center, Department of Hematology, Oslo University Hospital and KG Jebsen Center for B Cell Malignancies, University of Oslo, Oslo, Norway. fredrikschjesvold@gmail.com., Ludwig H; Department of Medicine I, Center for Medical Oncology and Hematology with Outpatient Department and Palliative Care, Wilhelminen Cancer Research Institute, Vienna., Delimpasi S; Bone Marrow Transplantation Unit and Department of Hematology, Evangelismos Hospital, Athens, Greece., Robak P; Department of Hemato-Oncology, University Hospital Ostrava, Ostrava, Czech Republic., Coriu D; University of Medicine and Pharmacy 'Carol Davila', Center of Hematology and Bone Marrow Transplantation, Fundeni Clinical Institute, Bucharest, Romania., Tomczak W; Department of Hemato-Oncology and Bone Marrow Transplantation, Medical University of Lublin., Pour L; Department of Internal Medicine, Hematology and Oncology, University Hospital Brno, Babak Myeloma Group, Faculty of Medicine, Masaryk University, Brno, Czech Republic., Spicka I; 1st Department of Medicine - Department of Hematology, First Faculty of Medicine, Charles University and General Hospital in Prague, Prague, Czech Republic., Dimopoulos MA; Department of Clinical Therapeutics, National and Kapodistrian University of Athens School of Medicine, Athens, Greece., Masszi T; Department of Internal Medicine and Haematology, Semmelweis University, Budapest, Hungary., Chernova NG; National Research Center for Haematology, Moscow, Russia., Sandberg A; Oncopeptides AB, Stockholm, Sweden., Thuresson M; Oncopeptides AB, Stockholm, Sweden., Norin S; Oncopeptides AB, Stockholm, Sweden., Bakker NA; Oncopeptides AB, Stockholm, Sweden., Mateos MV; Hospital Clínico Universitario de Salamanca/IBSAL/CIC, Salamanca, Spain., Richardson PG; Dana-Farber Cancer Institute, Boston, MA., Sonneveld P; Erasmus MC Cancer Institute, Rotterdam.

المصدر: Haematologica [Haematologica] 2024 Jul 01; Vol. 109 (7), pp. 2331-2336. Date of Electronic Publication: 2024 Jul 01.

نوع المنشور: Clinical Trial, Phase III; Multicenter Study; Research Support, Non-U.S. Gov't

بيانات الدورية: Publisher: Ferrata Storti Foundation Country of Publication: Italy NLM ID: 0417435 Publication Model: Electronic Cited Medium: Internet ISSN: 1592-8721 (Electronic) Linking ISSN: 03906078 NLM ISO Abbreviation: Haematologica Subsets: MEDLINE

مواضيع طبية MeSH: Antineoplastic Combined Chemotherapy Protocols*/therapeutic use , Antineoplastic Combined Chemotherapy Protocols*/adverse effects , Dexamethasone*/therapeutic use , Dexamethasone*/administration & dosage , Multiple Myeloma*/drug therapy , Quality of Life*, Aged ; Female ; Humans ; Male ; Middle Aged ; Drug Resistance, Neoplasm ; Neoplasm Recurrence, Local/drug therapy ; Phenylalanine/therapeutic use ; Phenylalanine/analogs & derivatives ; Recurrence ; Treatment Outcome

المؤلفون: Pour L; Department of Internal Medicine, Hematology and Oncology, University Hospital Brno, Babak Myeloma Group, Faculty of Medicine, Masaryk University, Brno, Czech Republic. pour.ludek@fnbrno.cz., Szarejko M; University Clinical Centre, Department of Hematology and Transplantology, Gdansk., Bila J; Clinic of Hematology, Clinical Center of Serbia, Faculty of Medicine, University of Belgrade, Belgrade., Schjesvold FH; Oslo Myeloma Center, Department of Hematology, Oslo University Hospital and KG Jebsen Center for B Cell Malignancies, University of Oslo, Oslo., Spicka I; 1^st Department of Medicine - Department of Hematology, First Faculty of Medicine, Charles University and General Hospital in Prague, Prague, Czech Republic., Maisnar V; 4^th Department of Medicine - Hematology, Charles University Hospital and Faculty of Medicine, Hradec Kralove, Czech Republic., Jurczyszyn A; Plasma Cell Dyscrasias Center, Department of Hematology, Jagiellonian University Faculty of Medicine, Krakow., Grudeva-Popova Z; Department of Clinical Oncology, Medical Faculty, Medical University of Plovdiv, Plovdic, Bulgaria., Hájek R; Department of Hematooncology, Faculty of Medicine, University of Ostrava, Ostrava, Czech Republic., Usenko G; City Clinical Hospital No. 4 of Dnipro City Council, Dnipro, Ukraine., Thuresson M; Oncopeptides AB, Stockholm., Norin S; Oncopeptides AB, Stockholm., Jarefors S; Oncopeptides AB, Stockholm., Bakker NA; Oncopeptides AB, Stockholm., Richardson PG; Dana-Farber Cancer Institute, Boston, MA., Mateos MV; Hospital Clínico Universitario de Salamanca/IBSAL/CIC, Salamanca.

المصدر: Haematologica [Haematologica] 2024 Mar 01; Vol. 109 (3), pp. 895-905. Date of Electronic Publication: 2024 Mar 01.

نوع المنشور: Clinical Trial, Phase III; Journal Article; Randomized Controlled Trial

بيانات الدورية: Publisher: Ferrata Storti Foundation Country of Publication: Italy NLM ID: 0417435 Publication Model: Electronic Cited Medium: Internet ISSN: 1592-8721 (Electronic) Linking ISSN: 03906078 NLM ISO Abbreviation: Haematologica Subsets: MEDLINE

مواضيع طبية MeSH: Antibodies, Monoclonal* , Hematopoietic Stem Cell Transplantation* , Melphalan*/analogs & derivatives , Multiple Myeloma*/diagnosis , Multiple Myeloma*/drug therapy , Neoplasms, Plasma Cell* , Neutropenia* , Phenylalanine*/analogs & derivatives, Humans ; Dexamethasone/therapeutic use ; Proteasome Inhibitors ; Transplantation, Autologous ; United States ; Antineoplastic Combined Chemotherapy Protocols/adverse effects

المؤلفون: Schjesvold FH; Oslo Myeloma Center, Department of Hematology, Oslo University Hospital, Oslo, Norway.; KG Jebsen Center for B Cell Malignancies, University of Oslo, Oslo, Norway., Ludwig H; Medical Department Center for Oncology, Hematology and Palliative Medicine, Wilhelminen Cancer Research Institute, Vienna, Austria., Mateos MV; Institute of Cancer Molecular and Cellular Biology, University Hospital of Salamanca, Salamanca, Spain., Larocca A; Myeloma Unit, Division of Hematology, University of Torino, Azienda Ospedaliero-Universitaria Città della Salute e della Scienza, Torino, Italy., Abdulhaq H; Department of Hematology and Oncology, University of California, San Francisco, Fresno, California, USA., Norin S; Clinical Science, Oncopeptides AB, Stockholm, Sweden., Thuresson M; Biostatistics, Oncopeptides AB, Stockholm, Sweden., Bakker NA; Clinical Science, Oncopeptides AB, Stockholm, Sweden., Richardson PG; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, USA., Sonneveld P; Department of Hematology, Erasmus MC Cancer Institute, Rotterdam, The Netherlands.

المصدر: European journal of haematology [Eur J Haematol] 2024 Mar; Vol. 112 (3), pp. 402-411. Date of Electronic Publication: 2023 Nov 15.

نوع المنشور: Journal Article

بيانات الدورية: Publisher: Blackwell Country of Publication: England NLM ID: 8703985 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1600-0609 (Electronic) Linking ISSN: 09024441 NLM ISO Abbreviation: Eur J Haematol Subsets: MEDLINE

مواضيع طبية MeSH: Multiple Myeloma*/diagnosis , Multiple Myeloma*/drug therapy , Hematopoietic Stem Cell Transplantation*, Melphalan/*analogs & derivatives , Phenylalanine/*analogs & derivatives , Thalidomide/*analogs & derivatives, Humans ; Melphalan/therapeutic use ; Alkylating Agents/therapeutic use ; Dexamethasone/adverse effects ; Transplantation, Autologous ; Antineoplastic Combined Chemotherapy Protocols/adverse effects

المؤلفون: Sonneveld P; Department of Hematology, Erasmus MC Cancer Institute, Rotterdam, The Netherlands. Electronic address: p.sonneveld@erasmusmc.nl., Richardson PG; Jerome Lipper Multiple Myeloma Center, Dana-Farber Cancer Institute, Boston, MA., Ludwig H; Medical Department Center for Oncology, Hematology and Palliative Medicine, Wilhelminen Cancer Research Institute, Vienna, Austria., Dimopoulos MA; Department of Clinical Therapeutics, School of Medicine, National and Kapodistrian University of Athens, Athens, Greece., Schjesvold FH; Oslo Myeloma Center, Department of Hematology, Oslo University Hospital, Oslo, Norway; KG Jebsen Center for B Cell Malignancies, University of Oslo, Oslo, Norway., Hájek R; Department of Hemato-oncology, University Hospital Ostrava, Ostrava, Czech Republic., Abdulhaq H; Department of Hemato-oncology, Faculty of Medicine, University of Ostrava, Ostrava, Czech Republic; Department of Medicine, University of California, San Francisco, Fresno Campus, CA., Thuresson M; Oncopeptides AB, Stockholm, Sweden., Norin S; Oncopeptides AB, Stockholm, Sweden., Bakker NA; Oncopeptides AB, Stockholm, Sweden., Mateos MV; University Hospital of Salamanca, Instituto de Investigación Biomédica de Salamanca, Salamanca, Spain; Institute of Cancer Molecular and Cellular Biology and CIBERONC, Salamanca, Spain.

المصدر: Clinical lymphoma, myeloma & leukemia [Clin Lymphoma Myeloma Leuk] 2023 Sep; Vol. 23 (9), pp. 687-696. Date of Electronic Publication: 2023 May 06.

نوع المنشور: Journal Article; Research Support, Non-U.S. Gov't

بيانات الدورية: Publisher: Elsevier Country of Publication: United States NLM ID: 101525386 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 2152-2669 (Electronic) Linking ISSN: 21522669 NLM ISO Abbreviation: Clin Lymphoma Myeloma Leuk Subsets: MEDLINE

مواضيع طبية MeSH: Multiple Myeloma*/drug therapy, Humans ; Antineoplastic Combined Chemotherapy Protocols/adverse effects ; Dexamethasone/therapeutic use ; Follow-Up Studies ; Melphalan/therapeutic use ; Risk Assessment ; Transplantation, Autologous ; Clinical Trials, Phase II as Topic ; Clinical Trials, Phase III as Topic ; Randomized Controlled Trials as Topic

المؤلفون: Groen K; Department of Hematology, Amsterdam UMC, Vrije Universiteit, the Netherlands.; Cancer Center Amsterdam, Treatment and Quality of Life, the Netherlands., Schjesvold FH; Department of Hematology, Oslo Myeloma Center, Oslo University Hospital, Norway.; KG Jebsen Center for B Cell Malignancies, University of Oslo, Norway., van der Holt B; Department of Hematology, HOVON Data Center, Erasmus MC Cancer Institute, Rotterdam, the Netherlands., Levin MD; Department of Internal Medicine, Albert Schweitzer Hospital, Dordrecht, the Netherlands., Seefat MR; Department of Hematology, Amsterdam UMC, Vrije Universiteit, the Netherlands.; Cancer Center Amsterdam, Treatment and Quality of Life, the Netherlands., Hansson M; Department of Hematology, Skåne University Hospital Lund, Sweden., Leys MBL; Department of Internal Medicine, Maasstad Hospital, Rotterdam, the Netherlands., Regelink JC; Department of Internal Medicine, Meander Medical Centre, Amersfoort, the Netherlands., Waage A; Institute of Clinical and Molecular Medicine, Norwegian University of Science and Technology (NTNU), Trondheim, Norway., Szatkowski D; Department of Oncology and Hematology, Førde Central Hospital, Norway., Axelsson P; Department of Internal Medicine, Helsingborg Hospital, Sweden., Hieu Do T; Haematology Department H 60, Roskilde Sjaelland University, Denmark., Svirskaite A; Department of Hematology, Aalborg University Hospital, Denmark., van der Spek E; Department of Internal Medicine, Rijnstate Hospital, Arnhem, the Netherlands., Haukas E; Department for Blood and Cancer Diseases, Stavanger University Hospital, Norway., Knut-Bojanowska D; Institute of Heamatology, Uddevalla Hospital, Sweden., Ypma PF; Department of Hematology, Haga Hospital, The Hague, the Netherlands., Blimark CH; Hematology Department, Sahlgrenska University Hospital, Gothenburg, Sweden., Mellqvist UH; Department of Internal Medicine, Sodra Alvsborgs Sjukhus, Boras, Sweden., van de Donk NWCJ; Department of Hematology, Amsterdam UMC, Vrije Universiteit, the Netherlands.; Cancer Center Amsterdam, Treatment and Quality of Life, the Netherlands., Sonneveld P; Department of Hematology, Erasmus MC Cancer Institute, Rotterdam, the Netherlands., Klostergaard A; Department of Hematology, Aarhus University Hospital, Denmark., Vangsted AJ; Department of Hematology, Rigshospitalet, Copenhagen, Denmark., Abildgaard N; Department of Hematology, Hematology Research Unit and Academy of Geriatric Research, Odense University Hospital and University of Southern Denmark, Denmark., Zweegman S; Department of Hematology, Amsterdam UMC, Vrije Universiteit, the Netherlands.; Cancer Center Amsterdam, Treatment and Quality of Life, the Netherlands.

المصدر: HemaSphere [Hemasphere] 2023 Aug 30; Vol. 7 (9), pp. e940. Date of Electronic Publication: 2023 Aug 30 (Print Publication: 2023).

نوع المنشور: Journal Article

بيانات الدورية: Publisher: Wiley Country of Publication: United States NLM ID: 101740619 Publication Model: eCollection Cited Medium: Internet ISSN: 2572-9241 (Electronic) Linking ISSN: 25729241 NLM ISO Abbreviation: Hemasphere Subsets: PubMed not MEDLINE